News and Announcements
Benitec Biopharma Annual Update 2015; Lists on the NASDAQ
- Published January 04, 2016 4:01PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Benitec Biopharma (ASX:BLT; NASDAQ:BNTC) is a clinical-stage, biotechnology company developing therapeutics based on its patented gene-silencing technology called ddRNAi.
Its unique therapies target specific genes, genetic disorders and infectious diseases including hepatitis C and B, wet Age-related Macular Degeneration (AMD) and Oculopharyngeal Muscular Dystrophy (OPMD). Benitec’s strategy is to develop its technology in-house, through partnerships with other biotechnology and pharma companies, as well as through out-licensing collaborations.
This year, the company has successfully listed on the NASDAQ, released positive in vitro data for its hepatitis B program and announced encouraging preliminary data from its Phase I/IIa hepatitis C clinical trial, the company’s lead program.
Benitec has a cash position, at 30 September 2015, of approximately AU$33 million. We expect to have significant advances on all of our programs in the next 12 months.
ABOUT BENITEC BIOPHARMA LIMITED
Benitec Biopharma Limited is a publicly listed (ASX:BLT) biotechnology company whose key assets are exclusive irrevocable worldwide rights to a platform technology which has the potential to permanently silence any gene associated with human diseases or conditions. Benitec Biopharma is demonstrating the efficacy and safety of this technology through collaboration with leading organisations globally.
Company Updates
BlackRock has named the next Economy. What this latest paper means for Private Market Investors.
BlackRock has put a name on something the smart money has been circling for two years. Its digital assets research team calls it the machine-native economy. The thesis fits in one line. AI is machine-native intelligence. Digital assets are machine-native money. Both are built on the same architecture, and they are converging into a single […]
Where’s the beef? Blackstone just answered the AI question.
In 1984, a fast food ad asked a question that became a catchphrase. Where’s the beef? Jon Gray, President of Blackstone, used that line this month in front of global LPs. It is the question every capital allocator is asking about AI. Trillions of dollars are going into chips, data centres and power. That is […]
The Best of Both Worlds: How Omnique Fund is Rewiring Real World Assets via Tokenisation
For decades, the playbook for Australia’s wholesale investors has remained relatively unchanged: pick between the slow-moving, illiquid reliability of tangible assets like property and gold, or chase the frictionless, high-velocity liquidity of public equity and digital markets. But as macroeconomic volatility spikes and a structural housing deficit reshapes private debt demand, sophisticated investors are demanding […]
Backed By Leading Investment Groups and Family Offices
